Virax Biolabs Group Limited Ordinary Shares (VRAX) — Cash Flow-to-Debt Ratio
Virax Biolabs Group Limited Ordinary Shares (VRAX) has a Cash Flow-to-Debt Ratio of -4.56x as of September 2025, meaning its operating cash flow of $-2.92 Million could theoretically repay -5% of its total liabilities ($641.52K) in one year. Explore VRAX operating cash flow to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Virax Biolabs Group Limited Ordinary Shares Cash Flow-to-Debt Ratio (2020–2025)
Historical debt coverage capacity for Virax Biolabs Group Limited Ordinary Shares across 6 annual periods. Also explore Virax Biolabs Group Limited Ordinary Sha assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Virax Biolabs Group Limited Ordinary Shares (2020–2025)
Year-by-year debt coverage analysis for Virax Biolabs Group Limited Ordinary Shares. For market capitalisation and broader financial context, see how much is Virax Biolabs Group Limited Ordinary Sha worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.73x | $-4.56 Million | $964.75K | ▲ +73.9% |
| 2024 | -18.10x | $-6.25 Million | $345.19K | ▼ -293.3% |
| 2023 | -4.60x | $-4.18 Million | $908.40K | ▼ -608.3% |
| 2022 | -0.65x | $-809.07K | $1.25 Million | ▲ +4.1% |
| 2021 | -0.68x | $-590.19K | $871.43K | ▼ -12.6% |
| 2020 | -0.60x | $-744.61K | $1.24 Million | — |